SCHEMBL2483673

SCHEMBL2483673

O=C(O)c1ccc(-c2ccncc2)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHUK O15111 2/20 0.56
DHODH Q02127 1/20 0.51
ACMSD Q8TDX5 3/20 0.48
HNF4A P41235 2/20 0.48
MCL1 Q07820 2/20 0.48
DHFR P00374 1/20 0.48
QDPR P09417 1/20 0.48
KDM4E B2RXH2 1/20 0.48
GFER P55789 1/20 0.48
KMT2A Q03164 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
FTO Q9C0B1 1/20 0.48
CDC7 O00311 2/20 0.47
ROCK2 O75116 1/20 0.47
MAP4K4 O95819 1/20 0.47
GSK3B P49841 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
MAPK14 Q16539 1/20 0.46
CDK9 P50750 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29436303 0.87 KMT2A (0.60) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL9550353 0.87 KMT2A (0.60) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL710222 0.87 KMT2A (0.60) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL30690398 0.85 KMT2A (0.62) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL30690397 0.85 KMT2A (0.62) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL33365 0.85 KMT2A (0.62) ACMSDHNF4AMCL1DHFRKDM4E
SCHEMBL5544965 0.85 HNF4A (0.70) CHUKACMSDHNF4AMCL1DHFR
SCHEMBL23421721 0.83 RXRB (0.57) CHUKDHODHACMSDHNF4AMCL1
SCHEMBL3104322 0.83 XDH (0.57) CHUKDHODHACMSDHNF4AQDPR
SCHEMBL205528 0.83 ROCK2 (0.55) CHUKDHODHACMSDHNF4AQDPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121736310-A Pb metal organic framework material with zeolite topology structure, preparation method and application 西安工程大学 2026-03-27 CN disclosed
CN-116313541-A Sulfur-modified copper/cuprous oxide electrode material and preparation method thereof 北京化工大学 2023-06-23 CN disclosed
US-8076348-B2 Acylguanidine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-12-13 US disclosed
EP-1923387-B1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2011-10-19 EP disclosed
US-20100168096-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-07-01 US disclosed
EP-1923387-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-05-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168096-A1 ACYLGUANIDINE DERIVATIVE OR SALT THEREOF HTR2B, HTR7, HTR3B CHUK 1036/4885DHODH 2882/4885ACMSD 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.